Action IMNN IMUNON, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Imunon, Inc.

Actions

IMNN

US15117N6022

Temps Différé Nasdaq
Autres places de cotation
 16:17:59 30/04/2024 		Varia. 5j. Varia. 1 janv.
1,29 USD -4,78% Graphique intraday de Imunon, Inc. -3,01% +89,71%
18/04 Imunon, Inc. Demande d'autorisation de commencer les essais sur l'homme pour IMNN-101 CI
01/04 IMUNON, INC. : HC Wainwright réitère son opinion positive sur le titre ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
IMUNON Reports Compliance with Nasdaq Listing Requirements
Top Midday Gainers
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
IMUNON Reports 2023 Financial Results and Provides Business Update
North American Morning Briefing : Stocks Set for -2-
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff
IMUNON Announces Leadership Change
Imunon, Inc. Announces Executive Changes
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMNN
  4. Actualités Imunon, Inc.
  5. Autres langues